---
figid: PMC11015836__OTT-17-307-g0003
pmcid: PMC11015836
image_filename: OTT-17-307-g0003.jpg
figure_link: /pmc/articles/PMC11015836/figure/f0003/
number: Figure 3
figure_title: ''
caption: Schematic representation of Ras/RAF/MEK/ERK signaling pathway activation
  or inhibition at different stages of treatment in our case.
article_title: MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib
  and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation
  and BRAF V600E.
citation: Xiang Tan, et al. Onco Targets Ther. 2024;17:307-312.
year: '2024'

doi: 10.2147/OTT.S454902
journal_title: OncoTargets and Therapy
journal_nlm_ta: Onco Targets Ther
publisher_name: Dove

keywords:
- MAP2K1
- furmonertinib
- lung adenocarcinoma
- EGFR
- mutation

---
